Clinicopathologic and Molecular Characterization of Low-Grade, Early-Stage, and HER2-Positive Invasive Breast Carcinoma
Publication: American Journal of Clinical Pathology, 2025, Vol. 163, No. Read More
Real-World Evidence From FLEX: Utility of MammaPrint in Guiding Treatment Planning for Patients Aged 70 and Older With Early-Stage Breast Cancer
Publication: ASCO® 2025 Authors: Reshma Mahtani, Ana Sandoval-Leon, Anna Read More
Association of MammaPrint and Clinical Outcomes by Race Among 5000 Individuals With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX
Publication: ASCO® 2025 Authors: Erin Cobain, Priyanka Sharma, Kent Read More
Molecular Insights Into HR+/HER2+ Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint Genomic Subtypes
Publication: ASCO® 2025 Authors: Laila Samiian, Adam Brufsky, Sahra Read More
MammaPrint® Reimbursement Indication Extended in Belgium
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 11, Read More
Anthracyclines and Treatment of Early-Stage Breast Cancer
For decades, anthracyclines have played an important role in Read More
How a Pregnant Woman Diagnosed With Breast Cancer Was Helped by MammaPrint
Aleseia Saunders was 32 when she felt a lump Read More
Laura J. van ’t Veer, PhD, Honored With 2024 William L. McGuire Memorial Lecture Award at SABCS 2024
SAN ANTONIO – Laura J. van ’t Veer, PhD, Read More
Gene Assay for MammaPrint May Predict Responses to Extended Letrozole in Low-Risk Breast Cancer Subsets
By Roman Fabbricatore | August 30, 2024 A gene Read More
Personalized Breast Cancer Treatment Offered by Texas Breast Center Utilizes Agendia
Texas Breast Center, led by renowned breast surgeon Dr. Read More
